Liver diseases, particularly those characterized by steatosis and fibrosis, represent major health challenges worldwide. Non-alcoholic fatty liver disease (NAFLD), a condition marked by abnormal fat accumulation in the liver, is one of the most common causes of liver pathology. If left unchecked, it can progress to liver fibrosis, cirrhosis, and even liver failure. Traditionally, liver biopsy has been the gold standard for assessing liver steatosis and fibrosis. However, this method has limitations such as invasiveness, risk of complications, and high cost. The emergence of non-invasive technologies like Ultrasound-based Dynamic Flow Frequency (UDFF) technology offers a promising alternative for assessing liver conditions. This paper reviews the latest advancements in UDFF technology, exploring its efficacy, diagnostic accuracy, and role in clinical practice. By comparing it to traditional methods, we demonstrate that UDFF offers a reliable and non-invasive method for evaluating liver steatosis and fibrosis, with potential to improve patient care and reduce healthcare costs
Liver diseases, particularly those characterized by steatosis and fibrosis, represent major health challenges worldwide. Non-alcoholic fatty liver disease (NAFLD), a condition marked by abnormal fat accumulation in the liver, is one of the most common causes of liver pathology. If left unchecked, it can progress to liver fibrosis, cirrhosis, and even liver failure. Traditionally, liver biopsy has been the gold standard for assessing liver steatosis and fibrosis. However, this method has limitations such as invasiveness, risk of complications, and high cost. The emergence of non-invasive technologies like Ultrasound-based Dynamic Flow Frequency (UDFF) technology offers a promising alternative for assessing liver conditions. This paper reviews the latest advancements in UDFF technology, exploring its efficacy, diagnostic accuracy, and role in clinical practice. By comparing it to traditional methods, we demonstrate that UDFF offers a reliable and non-invasive method for evaluating liver steatosis and fibrosis, with potential to improve patient care and reduce healthcare costs
| № | Author name | position | Name of organisation |
|---|---|---|---|
| 1 | Yusupalieva G.A. | ! | Tashkent Pediatric Medical Institute |
| 2 | Abzalova M.Y. | ! | Tashkent Pediatric Medical Institute |
| № | Name of reference |
|---|---|
| 1 | 1.Petta S., et al. (2020). 'Non-Invasive Assessment of Liver Steatosis and Fibrosis: A Review of Current Techniques.' Journalof Hepatology, 72(3), 618-635.2.BoursierJ., et al. (2016). 'Liver Steatosis and Fibrosis: Non-Invasive Diagnostic Methods.' Journalof Hepatology, 64(3), 424-437.3.Castera L., et al. (2019). 'Clinical Applications of FibroScan in Hepatology.' Hepatology, 70(1), 34-45.4.Dong Y., et al. (2018). 'Dynamic Flow Frequency Technology for Liver Fibrosis and Steatosis Assessment.' Journal of Ultrasound in Medicine, 37(7), 1749-1755. |